Despite recent downgrades from two major Wall Street firms, analysts maintain that Nutanix (NTNX) shares hold substantial upside potential, even as questions emerge about the pace of its near-term growth.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Future Proof Brands, maker of the popular ready-to-drink brand BeatBox, is laying off over 150 employees at its headquarters. The move comes weeks after announcing a $490 million majority stake acquisition by Anheuser-Busch, signaling corporate restructuring ahead of the deal's expected close in early 2026.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Months after the 'Crypto Black Friday' crash, allegations of platform instability and market manipulation continue to dog Binance, sparking fierce debate about trust and power in the digital asset space.
As the cryptocurrency market grapples with sustained selling pressure, a new analysis highlights significant vulnerabilities for two of the most recognizable digital assets, XRP and Dogecoin, projecting potential losses exceeding 50% in the coming year.
In a significant shift from its long-standing marketing playbook, Pizza Hut will not advertise during NBC's Super Bowl pre-game coverage this year, ending a tradition that spanned over a decade. The move comes as the chain undergoes a strategic review and reallocates its ad budget toward other sports and partnerships.
As gold breaches historic price levels, retirees face critical decisions on how to integrate the precious metal into their portfolios. We examine the trade-offs between physical bars, coins, and ETFs in a transformed market.
While an IRS extension grants an extra six months to file, experts caution that the April 15 payment deadline is non-negotiable. We break down the process, benefits, and common pitfalls for the millions considering this option.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Despite a bruising year, XRP's legal clarity, banking ambitions, and technical upgrades position it as a speculative recovery play for investors eyeing the next market cycle.
Baidu's flagship AI assistant, Ernie, has surpassed 200 million monthly active users, a milestone reported by the Wall Street Journal. The growth underscores Baidu's deepening integration of AI across its ecosystem amid fierce competition with domestic tech rivals.
Cotton futures extended losses on Friday, pressured by a stronger U.S. dollar and a significant year-over-year decline in export commitments. The market's focus remains on demand concerns as key metrics lag behind historical averages.
Corn futures extended losses on Friday, pressured by a strengthening U.S. dollar and weaker crude oil prices. Despite robust export sales data running ahead of historical pace, front-month contracts fell 5 to 5.5 cents, pushing the national average cash price lower.
Lean hog futures slipped lower on Friday, contrasting with a steady rise in the CME Lean Hog Index, as traders weighed softer cash prices against stronger wholesale pork values.
A dramatic reversal in precious metals markets saw silver crash 35% and gold fall 12% in a single session, testing a long-held crypto theory about capital rotation as Bitcoin demonstrates relative stability.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
While several stocks have posted impressive gains recently, not all momentum stories are built to last. We analyze one company with durable advantages and two where recent rallies may warrant skepticism.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
